- 基本信息
|
导师姓名：
|
任瑞宝
|
学科代码：
|
100201
|
|
|
性别：
|
男
|
学科名称：
|
内科学
|
|
培养单位：
|
附属瑞金医院
|
三级学科
|
血液病
|
|
导师类型：
|
博士生导师
|
专业领域名称：
|
|
|
联系方式：
|
rbren@sjtu.edu.cn
|
专业领域代码：
|
|
|
邮编：
|
200025
|
邮箱地址：
|
rbren830@163.com
|
- 研究方向 (点击浏览详细信息)
- 社会任职
| |
|
上海血液学研究所所长
|
|
上海交通大学"王宽诚“讲席教授
|
|
美国血液与肿瘤学杂志（JHO）副主编
|
|
美国Aging and Cancer副主编
|
|
上海生物工程学会荣誉理事长
|
|
医学前沿编委及北京大学学报医学版特邀编委
|
- 科研项目
| 20Z11900200 | 脐血细胞辅助治疗老年白血病的研究 | 市科委 |
2020-12~2024-11
|
400万元
| 课题负责人 |
| 81870112 | B淋巴细胞特异性BCR-ABL致癌通路的鉴定与机制研究 | 国家自然科学基金委
员会 |
2019-01~2022-12
|
55万元
| 课题负责人 |
| 2019CXJQ01 | 重大疾病的干细胞治疗研发与临床转化体系建立 | 上海市卫健委 |
2019-01~2023-12
|
4996.3万元
| 课题负责人 |
- 学术论文
|
Huo Y., Z. Sheng, D. Lu, D. Ellwanger, C. M. Li, O. Homann, S. Wang, H. Yin and R. Ren
|
Blinatumomab-induced T cell activation at single cell transcriptome resolution.
|
BMC Genomics
|
2021
|
22:145
|
|
Huang X., T. Ma, Y. Zhu, B. Jiao, S. Yu, K. Wang, J. Mi,
|
IRF4 and IRF8 expression are associated with clinical phenotype and predict the clinico-hematological response to hydroxyurea in essential thrombocythemia.
|
Frontiers of Medicine
|
2021
|
Online ahead of print
|
|
Zhang B., Y. Zhang, J. Zhang, P. Liu, B. Jiao, Z. Wang,
|
Focal adhesion kinase (FAK) inhibition synergizes with KRAS G12C inhibitors in treating cancer through the regulation of the FAK-YAP axis.
|
Adv Sci.
|
2021
|
Online ahead of print.
|
|
Li D., Y. Zhang, Q. Qiu, J. Wang, X. Zhao, B. Jiao, X. Zhang, S. Yu, P. Xu, Y. Dan, X. Xiao, P. Wang, M. Liu, Z. Xia, Z. Huang, R. Zhang, J. Li, X. Xie, Y. Zhang, C. Liu, P. Liu,
|
IRF8 impacts self-renewal of hematopoietic stem cells by regulating TLR9 signaling pathway of innate immune cells.
|
Adv Sci.
|
2021
|
Online ahead of print.
|
|
Wang P.; X. Xiao, Y. Zhang, B. Zhang, D. Li, M. Liu, X. Xie, C. Liu, P. Liu, R. Ren.
|
A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
|
J Hematol Oncol
|
2021
|
14:105
|
|
Xia Z., X. Zhang, P. Liu, R. Zhang, Z. Huang, D. Li, X. Xiao, M. Wu, N. Ning, Q. Zhang, J. Zhang, M. Liu, B. Jiao and R. Ren
|
GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner.
|
Cell Death Dis.
|
2021
|
12:54
|
|
Xiao X., P. Liu, D. Li, Z. Xia, P. Wang, X. Zhang, M. Liu, L. Liao, B. Jiao,
|
Combination therapy of BCR-ABL-positive B Cell Acute Lymphoblastic Leukemia by Tyrosine Kinase Inhibitor Dasatinib and c-JUN N-terminal Kinase inhibition.
|
J Hematol Oncol.
|
2020
|
13:80
|
|
Huang Z., M. Liu , D. Li , Y. Tan , R. Zhang , Z. Xia , P. Wang , B. Jiao , P. Liu,
|
PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS driven cancer cells.
|
J Biol Chem.
|
2020
|
295:18343-18354
|
|
Ning N., Y. Yu, M. Wu, R Zhang, T. Zhang, C. Zhu, L. Huang, C. Yun, C. Benes, J. Zhang, X. Deng, Q. Chen,
|
A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors.
|
Cancer Res.
|
2018
|
78(20):5949-5957
|
|
Liu P., B. Jiao, R. Zhang, H. Zhao, C. Zhang, M. Wu, D. Li, X. Zhao, Q. Qiu, J. Li and R. Ren.
|
Palmitoylacyltransferase Zdhhc9 Inactivation Mitigates Leukemogenic Potential of Oncogenic Nras.
|
Leukemia
|
2017
|
30:1225-8
|
|
Wu M., J. Huang, J. Zhang, C. Benes, B. Jiao,
|
N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation.
|
Molecular Cancer Therapeutics.
|
2017
|
16:57-67
|
|
Jiang J, F. Gui, Z. He, L. Li, Y. Li, S. Li, X. Wu, Z. Deng, X. Sun, X. Huang, W. Huang, S. Han, T. Zhang, Z. Wang, B. Jiao, S. Song, H. Wang, L. Chen, D. Zhou, Q. Liu,, J. Zhang, X. Deng.
|
Targeting BRK-positive breast cancers with small molecule kinase inhibitors.
|
Cancer Res.
|
2017
|
77:175-186
|
|